Katrin Schaudig

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Fezolinetant treatment for hot flashes associated with menopause: A plain language summary of the DAYLIGHT study.

Fezolinetant treatment for hot flashes associated with menopause: A plain language summary of the DAYLIGHT study.

Journal: Women's health (London, England)

Published: April 03, 2026

Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.

Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.

Journal: BMJ (Clinical research ed.)

Published: November 18, 2024

Time-efficient consultation hours in the department of gynecological endocrinology.

Time-efficient consultation hours in the department of gynecological endocrinology.

Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Published: September 01, 2024

Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.

Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.

Journal: Maturitas

Published: July 19, 2024

Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts' perspective.

Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts' perspective.

Journal: Expert review of clinical pharmacology

Published: June 06, 2023

Couplepause: deconstructing sick menopause and andropause during midlife.

Couplepause: deconstructing sick menopause and andropause during midlife.

Journal: The journal of sexual medicine

Published: May 11, 2023

Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone.

Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone.

Journal: Geburtshilfe und Frauenheilkunde

Published: June 29, 2021

Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone.

Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone.

Journal: Geburtshilfe und Frauenheilkunde

Published: February 04, 2021

Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 μg) and levonorgestrel (150 μg) in a randomized controlled trial.

Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 μg) and levonorgestrel (150 μg) in a randomized controlled trial.

Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Published: February 18, 2020

Hormone therapy for first-line management of menopausal symptoms: Practical recommendations.

Hormone therapy for first-line management of menopausal symptoms: Practical recommendations.

Journal: Women's health (London, England)

Published: August 06, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026